In this file
  1. Published ways to get in touch
  2. Account and patient-portal access
  3. For a payment or cancellation request
  4. For a medicine or shipment question
  5. If you have not joined yet
  6. When ordinary support is not enough
  7. Source notes

Getting help from MEDVi starts with identifying the kind of question you have. A login issue, a missing shipment, a prescription concern, and a renewal charge may need different people.

Use the official contact routes below rather than a phone number added to a search result by an unknown directory. We link to provider information and explain its limits; Is X Legitimate does not operate the provider’s support service.

Published ways to get in touch

The published telephone number for MEDVi is (323) 690-1564. An email route appears at help@medvi.org.

The published contact details identify a way to reach the business. They do not guarantee a response time or establish that a prescribing professional answers the telephone. Ask the representative to direct the request to the appropriate team.

Account and patient-portal access

Start from the official MEDVi website and follow its patient sign-in or help link. We did not establish a separate stable login address for this file.

If a password does not work, use the reset process from that verified site. Do not send a password, access code, full payment-card number, or medical record to this publication or to an unsolicited person offering to resolve the account.

For a payment or cancellation request

MEDVi provides links to legal and refund material, but not every legal destination could be established from the accessible evidence. Obtain the actual terms for the offer. Do not infer a refund right from a review, a guarantee headline, or an unanswered cancellation message.

Include the date and amount of the charge, the order or membership reference, and the specific action requested. Ask whether stopping MEDVi membership also stops any pending prescription. Keep the written response with the cancellation guidance.

For a medicine or shipment question

The public partner list includes Triad Rx, Red Rock, and Beaker. That list is a lead for questions, rather than confirmation of the pharmacy selected for a patient. The assigned dispenser and formulation still need to be identified.

Ask the pharmacy about preparation, labeling, storage, and the medicine it dispensed. Ask the treating clinician about suitability, side effects, or a change in instructions. A carrier tracking page can show parcel movement but cannot answer whether a medication remains suitable after a storage problem.

If you have not joined yet

How do the current offer and product claims address the issues in the FDA letter, and what precise medication would be supplied?

The captured weight-loss material did not support one dependable all-in current price for every MEDVi plan. Its QUAD per-dose advertising concerns a different product category. For weight management, request the named medication, supply period, care charges, and the amount taken at renewal.

Use the MEDVi provider file to put the support answer beside the medical and payment arrangements. A helpful sales conversation is useful, but it is not a completed assessment or a prescription.

When ordinary support is not enough

Do not wait for a routine support reply if you think you are having a medical emergency. For severe symptoms or an immediate threat to safety, seek urgent local help. For non-emergency medication concerns, contact your treating professional rather than improvising a change while waiting.

The medication side-effect guide explains how routine administrative contact differs from clinical and urgent care.

Source notes

Provider material describes the company’s own offer. Official medical references explain clinical and regulatory context; they do not endorse this publication or its commercial partner.

  1. MEDVi: provider, pharmacy, and contact disclosuresProvider-published information · Checked September 22, 2026
  2. FDA: MEDVi warning letter, February 20, 2026Regulatory / public agency · Checked September 22, 2026
  3. MEDVi QUAD: product and ingredient pageProvider-published information · Checked September 22, 2026
  4. FDA: concerns with unapproved GLP-1 drugsRegulatory / public agency · Checked September 22, 2026
  5. MedlinePlus: semaglutide injectionMedical reference · Checked September 22, 2026
  6. MedlinePlus: tirzepatide injectionMedical reference · Checked September 22, 2026
This article is educational research, not personal medical advice. A treating clinician should assess your circumstances. Research limits · Commercial disclosure · Contact information